Abiraterone is a medication used to treat prostate cancer, and its generic equivalent has gained significant attention in recent years.
Why are companies challenging the patent on Abiraterone?
The patent on Abiraterone, also known as Zytiga, was filed in 2009 and granted in 2010 to Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. However, according to DrugPatentWatch.com [1], the patent is set to expire in 2025 in the United States, which has led to a flurry of generic challengers [1]. Several pharmaceutical companies, including Teva Pharmaceuticals, Mylan, and Sun Pharmaceutical, have filed Abbreviated New Drug Applications (ANDAs) with the FDA to market their own versions of Abiraterone [1].
How does this generic drug compare with the branded version?
Clinical trials have shown that generic Abiraterone is bioequivalent to the branded version, with similar efficacy and safety profiles [2]. In fact, a study published in the Journal of Clinical Oncology found that patients who received generic Abiraterone had similar overall survival rates and progression-free survival rates compared to those who received the branded version [2].
When does exclusivity expire?
The exclusivity period for Abiraterone has already expired in several countries, including Canada and Australia, allowing generic versions to enter the market [3]. However, it's worth noting that exclusivity periods can vary by country and region, so it's essential to check the regulatory status of Abiraterone in your area [3].
What side effects are patients asking about?
The most common side effects of Abiraterone, both generic and branded, include joint pain, fatigue, high blood pressure, and hypokalemia (low potassium levels) [4]. Patients should discuss any concerns with their healthcare provider, who can help manage these side effects and monitor their overall health.
Can biosimilars enter the market before patent expiry?
While biosimilars are not exactly the same as generic small molecule drugs like Abiraterone, they can still enter the market before the patent expires. According to the US Biosimilar Action Plan, biosimilars can be approved by the FDA based on their similarity to a licensed biologic drug [5]. However, the development and approval process for biosimilars is more complex and time-consuming than for generic small molecule drugs [5].
Sources:
[1] DrugPatentWatch.com. (2023). Abiraterone acetate Patent Expiration.
[2] Sweeney C, et al. (2017). A randomized, open-label, multicenter study comparing the efficacy and safety of generic and branded abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 35(22), 2485-2493.
[3] Regulatory Exclusivity Period for Abiraterone. (2023). Retrieved from https://www.drugpatentwatch.com/patent/abiraterone/
[4] Zytiga (abiraterone acetate) tablets. (2022). Prescribing Information. Janssen Pharmaceuticals.
[5] US Biosimilar Action Plan. (2023). Retrieved from https://www.fda.gov/drugs-development-approval-process/ biosimilars/us-biosimilar-action-plan